Investissement Quebec and Lumira Ventures led a $41m round in KisoJi Biotechnology.

Investissement Quebec, a company that offers a range of financing solutions, and Lumira Ventures, a life sciences venture capital firm, led a $41m round in KisoJi Biotechnology, a company focused on the discovery and development of transformative antibody therapeutics, with participation from Fonds de solidarité FTQ, adMare BioInnovations, and Remiges Ventures. “By contributing to KisoJi Biotechnology’s financing round, Investissement Québec is reaffirming its commitment to supporting innovative companies in the life sciences industry, a key sector for the Québec economy. This funding will allow KisoJi Biotechnology to hit critical milestones in its operations, from completing preclinical activities to launching clinical trials, notably through a landmark agreement with Cancer Research UK, one of the world’s largest funders of cancer research, all the while helping move innovations from the R&D stage to the marketplace,” Bicha Ngo, Investissement Québec President and CEO.